Global biotech BioMarin Pharmaceutical Inc. (BMRN) has announced updated results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A.“This additional data is an important step toward a potential first treatment of its kind for this devastating disease,” said Professor John Pasi, M.B., chief investigator for the study.